Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Autografting

Effect of prior rituximab on high-dose therapy and autologous stem cell transplantation in follicular lymphoma

Bone Marrow Transplantation volume 40, pages 973–978 (2007)Cite this article

Abstract

Autologous stem-cell transplantation (ASCT) has been used in follicular lymphoma (FL) to achieve durable responses in first remission or in the relapsed or refractory settings. Addition of rituximab to chemotherapy for FL has been shown to improve survival. The impact of prior therapy with rituximab upon the effectiveness of high-dose therapy (HDT) and ASCT in patients with FL is unknown. We retrospectively reviewed consecutive patients with FL who underwent HDT and ASCT. Patients were categorized according to prior therapy with rituximab. Outcomes were compared between groups in all patients and in a well-matched subset. In all 35 patients received prior rituximab and 71 rituximab-naive patients were analyzed. The rituximab-naive group had a median overall survival (OS) that was not reached during follow-up, with a median relapse-free (RFS) survival of 49.9 months. The prior rituximab group also did not reach median OS and had a median RFS of 24.6 months. Survivals were not significantly different in this group or in the well-matched subset. In conclusion, these results suggest that the use of rituximab-based regimens for the treatment of FL does not compromise the effectiveness of HDT and ASCT as a salvage strategy in patients with FL.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4

Similar content being viewed by others

References

  1. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The non-Hodgkin's lymphoma classification project. Blood 1997; 89: 3909–3918 (0006-4971 (Print)).

    Google Scholar 

  2. McLaughlin P, Grillo-Lopez AJ, Link BK, Levy R, Czuczman MS, Williams ME et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998; 16: 2825–2833.

    Article  CAS  PubMed  Google Scholar 

  3. Feuring-Buske M, Kneba M, Unterhalt M, Engert A, Gramatzki M, Hiller E et al. IDEC-C2B8 (Rituximab) anti-CD20 antibody treatment in relapsed advanced-stage follicular lymphomas: results of a phase-II study of the German low-grade lymphoma study group. Ann Hematol 2000; 79: 493–500.

    Article  CAS  PubMed  Google Scholar 

  4. Marcus R, Imrie K, Belch A, Cunningham D, Flores E, Catalano J et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 2005; 105: 1417–1423.

    Article  CAS  PubMed  Google Scholar 

  5. Hiddemann W, Kneba M, Dreyling M, Schmitz N, Lengfelder E, Schmits R et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2005; 106: 3725–3732.

    Article  CAS  PubMed  Google Scholar 

  6. Schouten HC, Qian W, Kvaloy S, Porcellini A, Hagberg H, Johnson HE et al. High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: results from the randomized European CUP trial. J Clin Oncol 2003; 21: 3918–3927.

    Article  CAS  PubMed  Google Scholar 

  7. Rosenbaum PR, Rubin DB . The central role of the propensity score in observational studies for causal effects. Biometrika 1983; 70: 41–55.

    Article  Google Scholar 

  8. Parson LS . Reducing bias in a propensity score matched-pair sample using greedy matching techniques. Proceedings of the 26th Annual SAS Users Group International Conference; 2001.

  9. Young RC, Longo DL, Glatstein E, Ihde DC, Jaffe ES, DeVita Jr VT . The treatment of indolent lymphomas: watchful waiting v aggressive combined modality treatment. Semin Hematol 1988; 25 (Suppl 2): S11–S16.

    Google Scholar 

  10. Brice P, Bastion Y, Lepage E, Brousse N, Haioun C, Moreau P et al. Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d’Etude des Lymphomes Folliculaires. Groupe d’Etude des Lymphomes de l’Adulte. J Clin Oncol 1997; 15: 1110–1117.

    Article  CAS  PubMed  Google Scholar 

  11. Ardeshna KM, Smith P, Norton A, Hancock BW, Hoskin PJ, MacLennan KA et al. Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial. Lancet 2003; 362: 516–522 (1474-547X (Electronic)).

    Article  CAS  PubMed  Google Scholar 

  12. Johnson PW, Rohatiner AZ, Whelan JS, Price CG, Love S, Lim J et al. Patterns of survival in patients with recurrent follicular lymphoma: a 20-year study from a single center. J Clin Oncol 1995; 13: 140–147.

    Article  CAS  PubMed  Google Scholar 

  13. Freedman AS, Neuberg D, Mauch P, Soiffer RJ, Anderson KC, Fisher DC et al. Long-term follow-up of autologous bone marrow transplantation in patients with relapsed follicular lymphoma. Blood 1999; 94: 3325–3333.

    CAS  PubMed  Google Scholar 

  14. Apostolidis J, Gupta RK, Grenzelias D, Johnson PW, Pappa VI, Summers KE et al. High-dose therapy with autologous bone marrow support as consolidation of remission in follicular lymphoma: long-term clinical and molecular follow-up. J Clin Oncol 2000; 18: 527–536.

    Article  CAS  PubMed  Google Scholar 

  15. Hagenbeek A, Van Glabbeke M, Teodorovic I . The role of rituximab maintenance treatment in relapsed follicular NHL: an interim analysis of the EORTC randomized intergroup trial (Abstract). Annals of Oncology 2006; 16: 52–61.

    Google Scholar 

  16. Corradini P, Ladetto M, Zallio F, Astolfi M, Rizzo E, Sametti S et al. Long-term follow-up of indolent lymphoma patients treated with high-dose sequential chemotherapy and autografting: evidence that durable molecular and clinical remission frequently can be attained only in follicular subtypes. J Clin Oncol 2004; 22: 1460–1468.

    Article  PubMed  Google Scholar 

  17. Pohlman B, Rybicki L, Kuczkowski E, Bolwell B . Final analysis of a randomized, phase III, trial using etoposide and G-CSF with or without rituximab for peripheral stem cell mobilization in B-cell non-Hodgkins lymphoma. Blood (ASH Annual Meeting Abstracts) 2005; 106: 300.

    Google Scholar 

  18. Hochster HS, Weller E, Ryan T, Habermann TM, Gascoyne R, Frankel SR et al. Results of E1496: a phase III trial of CVP with or without maintenance with rituximab in advanced indolent lymphoma (Abstract). J Clin Oncol 2004; 22: 558–6502.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Hematologic Oncology and Blood Disorders, Cleveland Clinic Taussig Cancer Center, Cleveland, OH, USA

    T Y Kang, B J Bolwell, S G Thakkar, S Brown, R Dean, M A Sekeres, A Advani, R Sobecks, M Kalaycio, B Pohlman & J W Sweetenham

  2. Quantitative Health Sciences, Cleveland Clinic Taussig Cancer Center, Cleveland, OH, USA

    L A Rybicki

Authors
  1. T Y Kang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. L A Rybicki
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. B J Bolwell
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. S G Thakkar
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. S Brown
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. R Dean
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. M A Sekeres
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. A Advani
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. R Sobecks
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. M Kalaycio
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. B Pohlman
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. J W Sweetenham
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to T Y Kang.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kang, T., Rybicki, L., Bolwell, B. et al. Effect of prior rituximab on high-dose therapy and autologous stem cell transplantation in follicular lymphoma. Bone Marrow Transplant 40, 973–978 (2007). https://doi.org/10.1038/sj.bmt.1705849

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1705849

Keywords

Search

Advanced search

Quick links